Merck, Inc.
🇵🇭Philippines
Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)
Phase 4
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: Infliximab (Remicade)
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT00794898
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00792935
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
Phase 2
Completed
- Conditions
- Primary Insomnia
- Interventions
- Drug: SuvorexantDrug: Dose-matched Placebo to Suvorexant
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 254
- Registration Number
- NCT00792298
MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: MK-1006Drug: Placebo
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00791661
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14671
- Registration Number
- NCT00790205
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: MK8245
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT00790556
A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)
Phase 1
Completed
- Conditions
- Hypertension
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00789321
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
Phase 2
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: PegIntron (peginterferon alfa-2b)
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00787371
A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT00782951
A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)
Phase 1
Completed
- Conditions
- The Methodology Assessment of Glucose Dependent Insulin Secretion
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00782418
© Copyright 2025. All Rights Reserved by MedPath